Tirzepatide
Dual GIP/GLP-1 agonist for weight loss and blood sugar control. Clinically proven efficacy up to −22% of initial body weight.
What is Tirzepatide?
Tirzepatide (brand names Mounjaro, Zepbound) is an injectable medication and the first-in-class dual GIP and GLP-1 receptor agonist. Unlike semaglutide, it activates two hormonal pathways, delivering more pronounced weight loss effects.
Injection Protocol
Starting dose: 2.5 mg (2500 mcg) subcutaneously once weekly for 4 weeks.
Titration: Increase by 2.5 mg every 4 weeks as tolerated. Target dose: 5 to 15 mg weekly.
Injection sites: Abdomen, thigh, or upper arm. Rotate sites weekly.
Vial Reconstitution
Tirzepatide comes in 10 mg, 15 mg, or 30 mg vials. When reconstituting with 1 ml bacteriostatic water:
- 10 mg vial → 10 mg/ml → 2.5 mg = 0.25 ml = 25 units (U-100)
- 15 mg vial → 15 mg/ml → 5 mg = 0.33 ml = 33 units (U-100)
- 30 mg vial → 30 mg/ml → 7.5 mg = 0.25 ml = 25 units (U-100)
Storage
Unreconstituted vial: refrigerate (+2°C to +8°C). After reconstitution: refrigerate, use within 28 days. Do not freeze.
Important Warnings
- Do not use if you have pancreatitis or medullary thyroid cancer.
- Rapid weight loss can cause muscle mass loss — track protein intake carefully.
- May significantly reduce appetite — ensure adequate nutrition.
Rapid weight loss burns muscle. Avoid Ozempic face by tracking your protein intake.
Check Protein Norm